Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial

OBJECTIVE: In relapsing–remitting multiple sclerosis (RRMS), suboptimal adherence to injectable disease-modifying therapies (iDMTs; interferon β-1a/b, glatiramer acetate) is common, reducing their effectiveness. Patient retention on oral fingolimod and iDMTs was evaluated in PREFERMS, a randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cree, Bruce A.C., Arnold, Douglas L., Cascione, Mark, Fox, Edward J., Williams, Ian M., Meng, Xiangyi, Schofield, Lesley, Tenenbaum, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964857/
https://www.ncbi.nlm.nih.gov/pubmed/29844796
http://dx.doi.org/10.1177/1756286418774338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964857/
https://www.ncbi.nlm.nih.gov/pubmed/29844796
http://dx.doi.org/10.1177/1756286418774338

Ejemplares similares